Teva to Buy Allergan Generics in $40.5 Billion Deal (NYSE: TEVA)

Teva to Buy Allergan Generics: Teva announced Monday it will buy Allergan Generics in a deal valued at $40.5 billion. The move further cements Teva's position as the world's biggest seller of off-brand drugs, and it allows Allergan to focus on its higher-margin brand-name drugs. Here's everything investors need to know about the deal now... Tags: Allergan stock , NYSE: AGN , NYSE: TEVA , Teva Allergan , Teva Allergan deal , Teva and Allergan , Teva buys allergan , Teva stock , Teva to Buy Allergan Generics To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Teva to Buy Allergan Generics in $40.5 Billion Deal (NYSE: TEVA) appeared first on Money Morning - We Make Investing Profitable .